Total
0
Shares
Race Oncology (ASX:RAC) - Managing Director & CEO, Phil Lynch - The Market Herald
Managing Director & CEO, Phil Lynch
Source: Race Oncology
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Race Oncology (RAC) is set to team up with The University of Newcastle to investigate the heart safety of its Bisantrene drug over chemotherapeutics
  • This trial will investigate Race's treatment in comparison with anthracycline therapeutics, which are commonly used in the treatment of breast cancer and can often cause cardiotoxicity
  • Race affirms Bisantrene's heart safety has been demonstrated in clinical trials, but how it avoids causing cardiotoxicity is unknown
  • Cardiotoxicity researchers at the University of Newcastle will lead the project with preclinical studies to start immediately, and results are expected over the coming 12 months
  • Race Oncology shares are up 1.61 per cent this morning, trading at $3.16

Race Oncology (RAC) is set to team up with The University of Newcastle to investigate the heart safety of its Bisantrene drug over chemotherapeutics.

Specifically, the collaborative preclinical programme is set to assess the molecular mechanisms of Bisantrene's heart safety capabilities, using current molecular biology techniques.

According to Race, Bisantrene is a "small molecule anti-cancer drug which has potential as both a low dose, highly targeted precision oncology agent and a high dose, less cardiotoxic chemotherapeutic."

While the drug's heart safety has been demonstrated in clinical trials, how it avoids causing cardiotoxicity is unknown.

This trial will investigate Race's treatment in comparison with anthracycline therapeutics which are commonly used in the treatment of breast cancer.

Cardiotoxicity researchers at the University of Newcastle, Associate Professors Aaron Sverdlov and Doan Ngo, will lead the project with preclinical studies to start immediately.

Results are expected to be reported over the coming 12 months.

Race Oncology's Chief Scientific Officer Dr Daniel Tillett spoke highly of the upcoming studies.

"This is an exciting development for Race and we are looking forward to collaborating with Assistant Professors Sverdlov and Ngo on this important project. Understanding how Bisantrene works at a molecular level to avoid damage to the heart will aid all our clinical plans," he commented.

Race Oncology shares are up 1.61 per cent this morning, trading at $3.16 at 10:49 am AEST.

RAC by the numbers
More From The Market Herald
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.
Microequities Asset Management (ASX:MAM) posts 140pc boost to half-yearly profit

" Patrys (ASX:PAB) receives $600k R&D tax incentive refund

Patrys (PAB), through its wholly owned Nucleus Therapeutics subsidiary, has received a research and development (R&D) tax incentive refund of $626,780 for the